AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin

• Project for the preclinical development of ATL-105, a recombinant alpha-1 antitrypsin (AAT)-based drug platform for the treatment of inflammatory diseases, viral infections, and rare respiratory diseases
• SPRIND supports the development of ATL-105 for the treatment of viral respiratory diseases in various disease models

Munich, Germany – 06.02.2024 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), today announces the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND). This project is a key step in the development of the innovative ATL-105 drug platform for the treatment of respiratory diseases.

As part of the collaboration with SPRIND, ATL-105 will be tested in various disease models for viral diseases of the respiratory tract. Amongst others, state-of-the-art "lung-on-a-chip" models with human lung tissue and computer-aided simulations of the distribution of ATL-105 in the lungs will be used. These innovative new technologies make it possible to generate clinically relevant data on the effect of the compound in the human lung even before clinical trials begin. SPRIND supports the testing and provides funding for the project work.

Sigrid Koeth, Innovation Manager at SPRIND, emphasizes the importance of the project: "With SPRIND, we want to create disruptive innovations from Germany. The collaboration with AATec Medical is an example of our commitment to combining scientific research with entrepreneurial action and thus promoting innovative solutions in the healthcare sector."

Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, comments on the collaboration: "The partnership with SPRIND enables us to accelerate our research and development work and realize our innovation potential faster. Our goal is to utilize recombinant alpha-1 antitrypsin with state-of-the-art protein inhalation technology to develop effective solutions for the growing global threat of respiratory diseases. In addition to the treatment of respiratory viral infections, we are focusing on inflammatory diseases such as COPD, asthma, acute respiratory distress syndrome (ARDS) and other respiratory diseases with high unmet medical needs."

Alpha-1-antitrypsin (AAT) is a human serine protease inhibitor with immunomodulatory and broad-spectrum antiviral activity. To achieve an optimal local effect in the respiratory tract, AATec is working with partners to develop targeted drugs in combination with user-friendly inhalers that enable broad and cost-effective application.

About AATec
AATec Medical GmbH is a biotechnology company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial with the first product candidate ATL-105 for inhaled application in respiratory diseases. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit and follow us on .

Contact
AATec Medical GmbH
Dr. Rüdiger Jankowsky, CEO
Email:

Media Contact
MC Services
Katja Arnold, Julia von Hummel
Email:
Phone: +49 (0)89 2102280